3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
5
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled